An interventional study of Risk-based CAD management and Invasive coronary angiography in Transcatheter Aortic Valve Replacement, Coronary Artery Disease and Heart Disease Risk Factors, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Insel Gruppe AG, University Hospital Bern.
Among the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern, this one is the 5th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2025, is one of 18 with no phase, and was the 33rd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →6 of the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern are open now, in 6 countries. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Insel Gruppe AG, University Hospital Bern · Sites in Bosnia and Herzegovina, Italy, Switzerland
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+ · Healthy volunteers
Insel Gruppe AG, University Hospital Bern · Sites in France, Germany, Japan and 1 more country
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 4 3
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 546 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 100 across the 23 interventional studies, 120 across the 11 observational. Of the 28 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
1 of the studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Coronary Artery Disease by Insel Gruppe AG, University Hospital Bern, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronary artery disease (CAD) and aortic stenosis frequently coincide. Before valve intervention, invasive coronary angiography is routinely performed to assess coronary status.
As the impact of percutaneous revascularization on clinical outcomes beyond symptom improvement is subject to debate and treatment of aortic stenosis itself reduces ischemic burden and symptoms, the benefit/risk balance of routine invasive coronary angiography prior to transcatheter aortic valve implantation (TAVI) is unclear.
The CAT Trial aims to compare a non-invasive risk management strategy to routine invasive coronary angiography for the assessment of coronary artery disease in patients with severe, symptomatic aortic stenosis selected to undergo TAVI with respect to adverse clinical outcomes at 3 years (primary objective) and patient reported outcome measures (secondary objective).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
if mean gradient \<40 mmHg and peak velocity (Vmax) \<4 m/s and stroke volume indexed to body surface area (SVi) ≤ 35 mL/m2 and ≥50% then if CT-derived aortic valve calcium score >2000 Agatston units in men, >1200 in women
OR
if mean gradient \<40 mmHg and Vmax \<4 m/s and SVi ≤ 35 mL/m2 and LVEF \<50% then if CT-derived aortic valve calcification >2000 Agatston units in men, >1200 in women OR if low-dose dobutamine stress echocardiography with flow reserve (>20% increase in stroke volume) and AVA ≤1cm2
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will not undergo routine coronary angiography prior to TAVI. Statin treatment of at least moderate intensity is recommended.
Diagnostic Test: Risk-based CAD management
Routine invasive coronary angiography prior to TAVI. Percutaneous coronary intervention (PCI) recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
Diagnostic Test: Invasive coronary angiography
Patients will not undergo routine coronary angiography prior to TAVI. Statin treatment of at least moderate intensity is recommended.
Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
Composite of all-cause death, myocardial infarction, any stroke, and heart failure hospitalization
Primary endpoint. Valve Academic Research Consortium (VARC)-3 definitions)
Time frame: 3 years
Patient reported health status
Seattle Angina Questionnaire-7 (score from 0 to 100, with higher values indicating better health)
Time frame: 3 months, 1, 3 and 5 years
Patient reported health status
Kansas City Cardiomyopathy Questionnaire-12 (score from 0 to 100, with higher values indicating better health)
Time frame: 3 months, 1, 3 and 5 years
Patient reported health status
EuroQol 5D 5L (index scores range from -0.59 to 1, with higher values indicating better health)
Time frame: 3 months, 1, 3 and 5 years
Rate of all cause death
Time frame: 3 months, 1, 3 and 5 years
Rate of cardiovascular death
(VARC-3)
Time frame: 3 months, 1, 3 and 5 years
Rate of disabling strokes
(VARC-3)
Time frame: 3 months, 1, 3 and 5 years
Rate of myocardial infarction
(VARC-3)
Time frame: 3 months, 1, 3 and 5 years
Rate of unplanned, urgent revascularization
Time frame: 3 months, 1, 3 and 5 years
Rate of elective revascularization
Time frame: 3 months, 1, 3 and 5 years
Rate of cardiovascular hospitalization
Time frame: 3 months, 1, 3 and 5 years
Rate of heart failure hospitalization
Time frame: 3 months, 1, 3 and 5 years
Rate of bleeding
(VARC-3)
Time frame: 3 months, 1, 3 and 5 years
Rate of acute kidney injury
(VARC-3)
Time frame: 3 months, 1, 3 and 5 years
Rate of tachyarrhythmia
(VARC-3)
Time frame: 3 months, 1, 3 and 5 years
Rate of major vascular complications
(VARC-3)
Time frame: 3months, 1, 3 and 5 years
Rate of major cardiac structural complications
(VARC-3)
Time frame: 3 months, 1, 3 and 5 years
Rate of permanent pacemaker implantation
(VARC-3)
Time frame: 3 months, 1, 3 and 5 years
Plan to share: Yes — sharing via https://boris.unibe.ch platform
Supporting information: Study protocol, Clinical study report
Time frame: after study completion
Access criteria: Data will be made available upon reasonable request
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2030, 60 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 60 months is above that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →